NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
Clinical Trials
6 trialsNCT05113368 2025-08-21
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT02584465 2023-09-06
REGOVAR
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT02307500 2022-09-10
RESOUND
Istituto Clinico Humanitas
Phase 2 Completed
NCT02736305 2022-06-13
Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
National Cancer Centre, Singapore
Phase 2 Completed
NCT02278783 2017-10-06
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
University of Utah
Phase 2 Terminated